Fangli Pei

Supplementary Material 1: 14 herbs of LSNYP.

Supplementary Material 1: 14 herbs of LSNYP.

Supplementary Material 2: 114 Potential active components.

Supplementary Material 2: 114 Potential active components.

Supplementary Material 3: 217 potential therapeutic targets.

Supplementary Material 3: 217 potential therapeutic targets.

Supplementary Material 4: Main quality control components were identified by UHPLC-Q/TOF-MS.

Supplementary Material 4: Main quality control components were identified by UHPLC-Q/TOF-MS.

OBJECTIVE: This study aimed to investigate the mechanisms underlying Nuclear Receptor Subfamily 5 Group A Member 1 (NR5A1, encoding SF-1) hypomethylation in endometriosis (EMs) and to evaluate the effects of Luoshi Neiyi Prescription (LSNYP…

Abstract Background Luoshi Neiyi prescription (LSNYP) is a traditional Chinese medicine that has a clinical effect on endometriosis (EMs). This study combined network pharmacology with experimental validation to explore its potential molecu…

Abstract Background Luoshi Neiyi prescription (LSNYP) is a traditional Chinese medicine that has a clinical effect on endometriosis (EMs). This study combined network pharmacology with experimental validation to explore its potential molecu…

BACKGROUND: Luoshi Neiyi prescription (LSNYP) is a traditional Chinese medicine that has a clinical effect on endometriosis (EMs). This study combined network pharmacology with experimental validation to explore its potential molecular mech…

ETHNOPHARMACOLOGICAL RELEVANCE: Endometriosis (EMS) is a common gynecological disease that causes dysmenorrhea, chronic pelvic pain and infertility. Luoshi Neiyi Prescription (LSNYP), a traditional Chinese medicine (TCM) formula, is used to…

INTRODUCTION: Endometriosis (EMs) is characterized by ectopic growth of active endometrial tissue outside the uterus. The Luoshi Neiyi prescription (LSNYP) has been extensively used for treating EMs in China. However, data on the active che…